Nisa Investment Advisors LLC Has $241,000 Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

Nisa Investment Advisors LLC lifted its stake in Verve Therapeutics, Inc. (NASDAQ:VERV) by 465.4% in the fourth quarter, HoldingsChannel reports. The firm owned 42,781 shares of the company’s stock after purchasing an additional 35,214 shares during the period. Nisa Investment Advisors LLC’s holdings in Verve Therapeutics were worth $241,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. GAMMA Investing LLC boosted its holdings in shares of Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock worth $34,000 after buying an additional 3,964 shares during the period. Creative Planning acquired a new position in Verve Therapeutics in the 3rd quarter worth approximately $50,000. PFG Investments LLC purchased a new position in Verve Therapeutics during the 3rd quarter worth approximately $53,000. Erste Asset Management GmbH acquired a new stake in Verve Therapeutics during the 3rd quarter valued at $56,000. Finally, Aigen Investment Management LP purchased a new stake in shares of Verve Therapeutics in the third quarter valued at $74,000. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Canaccord Genuity Group upped their price target on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Royal Bank of Canada reduced their price target on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, HC Wainwright lowered their price objective on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th.

Verve Therapeutics Price Performance

Shares of VERV stock opened at $7.70 on Thursday. Verve Therapeutics, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $19.34. The stock’s 50-day moving average is $6.13 and its two-hundred day moving average is $5.84. The firm has a market cap of $651.88 million, a P/E ratio of -3.13 and a beta of 1.68.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.11. The firm had revenue of $6.87 million for the quarter, compared to the consensus estimate of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The firm’s revenue was up 120.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.72) earnings per share. As a group, research analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.